Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Hempling

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
American Journal of Clinical Oncology|October 22, 1998
Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancerR E Hempling, M S Piver, G H Eltabbakh, et al.
Gynecologic Oncology|February 18, 1999
Effects of IL-12 on human ovarian tumors engrafted into SCID miceD F Silver, R E Hempling, M S Piver, et al.
Obstetrics and Gynecology|September 1, 1985
Pregnancy-associated group B streptococcal endocarditis: a report of two fatal casesD J Sexton, S G Rockson, R E Hempling, et al.
Gynecologic Oncology|May 8, 1998
Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancerF O Recio, M S Piver, R E Hempling, et al.
Obstetrics and Gynecology|May 8, 1998
Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatinG H Eltabbakh, R E Hempling, F O Recio, et al.
Cancer|November 15, 1996
Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapyF O Recio, M S Piver, R E Hempling, et al.
Gynecologic Oncology|June 1, 2000
Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient miceD F Silver, R E Hempling, M S Piver, et al.
Gynecologic Oncology|December 1, 1996
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancerJ M Goldberg, M S Piver, R E Hempling, et al.
European Journal of Gynaecological Oncology|January 1, 1994
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trialR E Hempling, M S Piver, T R Baker, et al.
Obstetrics and Gynecology|June 1, 1997
Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control studyR E Hempling, C Wong, M S Piver, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Oncology|October 22, 1998
Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancerR E Hempling, M S Piver, G H Eltabbakh, et al.
Gynecologic Oncology|February 18, 1999
Effects of IL-12 on human ovarian tumors engrafted into SCID miceD F Silver, R E Hempling, M S Piver, et al.
Obstetrics and Gynecology|September 1, 1985
Pregnancy-associated group B streptococcal endocarditis: a report of two fatal casesD J Sexton, S G Rockson, R E Hempling, et al.
Gynecologic Oncology|May 8, 1998
Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancerF O Recio, M S Piver, R E Hempling, et al.
Obstetrics and Gynecology|May 8, 1998
Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatinG H Eltabbakh, R E Hempling, F O Recio, et al.
Cancer|November 15, 1996
Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapyF O Recio, M S Piver, R E Hempling, et al.
Gynecologic Oncology|June 1, 2000
Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient miceD F Silver, R E Hempling, M S Piver, et al.
Gynecologic Oncology|December 1, 1996
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancerJ M Goldberg, M S Piver, R E Hempling, et al.
European Journal of Gynaecological Oncology|January 1, 1994
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trialR E Hempling, M S Piver, T R Baker, et al.
Obstetrics and Gynecology|June 1, 1997
Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control studyR E Hempling, C Wong, M S Piver, et al.
Pageof 6